Yolk shell mesoporous silica coated gold nanostar and preparation method and application thereof
By constructing mesoporous silica-coated gold nanostars of egg yolk shells, the problem of insufficient carrier efficiency and stability in existing tumor treatments is solved, multi-drug delivery and photothermal collaborative treatment are achieved, which significantly inhibits the growth of cervical cancer cells. A novel choice for multimodal therapy.
Patent Information
- Application Number
- CN202410990080.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-23
AI Technical Summary
The existing tumor treatment methods cannot meet clinical needs, especially the treatment of cervical cancer. The effect of a single treatment method is limited and the lack of effective carriers for multimodal combined treatment can affect the treatment effect.
Develop a mesoporous silica-coated gold nanostar (GNS@YSMS) by constructing mesoporous silica shell on the surface of gold nanostars, improving drug-loading efficiency and stability, and combining photothermal effects, for use in Multi-drug delivery platform that synergistically inhibits tumor cells.
Achieve efficient multi-drug delivery, significantly improve the load capacity of metal ions, proteins and nucleic acid drugs, enhance photothermal stability, and provide a safe and efficient multi-mode treatment plan, especially suitable for local cervical cancer treat.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and in particular to an egg yolk shell mesoporous silica-coated gold nanostar and a preparation method and application thereof. Background Art
[0002] Tumors are major diseases that threaten human health. Cervical cancer is a malignant tumor with a female incidence second only to breast cancer. The incidence and mortality of cervical cancer are still on the rise. Currently, single treatment can no longer meet clinical needs, and new treatment methods are urgently needed. Combination therapy has become a new hope for tumor treatment, and multifunctional and biocompatible drug carriers will provide important support for combination therapy.
[0003] Therefore, multimodal combination therapy has attracted more and more attention. For example, PD-1 combined with chemotherapy and EGFR combined with chemotherapy have become the first-line treatment options for their respective cancers. It can be seen that multimodal therapy will be the mainstream of cancer treatment in the future, and it is very meaningful to develop a drug delivery system suitable for multimodal therapy. Summary of the invention
[0004] The invention provides an egg yolk shell mesoporous silica coated gold nanostar and a preparation method and application thereof.
[0005] A yolk shell mesoporous silica coated gold nanostar (GNS@YSMS), comprising: Core, gold nanostar; The shell is mesoporous silica.
[0006] The yolk-shell mesoporous silica-coated gold nanostar provided by the present invention removes the internal structure of traditional mesoporous silica and retains the shell, thereby maximizing the drug loading efficiency and retaining the drug loading and sustained release capabilities. Nanogold also has the advantage of high biosafety and is a promising photothermal therapeutic agent in clinical tumor photothermal therapy. Compared with spherical gold nanoparticles, the shape change of non-spherical gold nanoparticles such as gold nanorods and gold nanostars causes the surface plasma resonance wavelength to red shift, thereby improving near-infrared absorption and photothermal conversion efficiency. However, non-spherical gold nanoparticles are unstable. The present invention constructs mesoporous silica-coated gold nanostars into the mesoporous silica of the yolk shell to prepare a yolk-shell mesoporous silica-coated gold nanostar (GNS@YSMS). The introduction of GNS imparts a photothermal effect, and the yolk-shell mesoporous silica increases the stability of GNS.
[0007] Specifically, the gold nanostar is coated in the yolk shell mesoporous silica, and the diameter of the core is 50-100 nm.
[0008] Specifically, the gold nanostars are coated in the egg yolk shell mesoporous silica, and the thickness of the shell is 75-150 nm.
[0009] The present invention also provides a method for preparing the egg yolk shell mesoporous silica-coated gold nanostars as described above, comprising: 1) Preparation of gold nanostars (GNS); 2) coating the surface of the gold nanostar with dense silica to prepare GNS@SiO2 (gold nanostar coated with dense silica); 3) GNS@SiO2 reacts with tetraethyl orthosilicate (TEOS), dimethyldimethoxysilane (BTSE) and hexadecyltrimethylammonium bromide (CTAB) to prepare GNS@SiO2@mSiO2; 4) GNS@SiO2@mSiO2 was etched with sodium carbonate to produce yolk-shell mesoporous silica-coated gold nanostars (GNS@YSMS).
[0010] Preferably, polyvinyl pyrrolidone (PVP) is used for functionalization during the preparation of the gold nanostars. Studies have found that gold nanostars functionalized with polyvinyl pyrrolidone can be better coated with silica than those functionalized with other materials (such as thiol PEG, PEG-SH).
[0011] Specifically, the preparation method of the gold nanostar comprises: firstly reacting HAuCl4, concentrated hydrochloric acid and gold seed in a solution; then adding AgNO3 and ascorbic acid to react; and finally adding polyvinyl pyrrolidone to react to obtain a gold nanostar aqueous solution.
[0012] Preferably, 100 mL of 0.25 mM HAuCl4 deionized water solution is prepared, 8.33 μL of 36%-38% concentrated hydrochloric acid is added, and the mixture is mixed by magnetic stirring. Then, 1 mL of gold seed aqueous solution is added, and stirring is continued. At the same time, 1 mL of 3 mM AgNO3 deionized water solution and 0.5 mL of 100 mM ascorbic acid deionized water solution are added. After reacting for 1 min, 0.3 mL of 15 mg / mL polyvinyl pyrrolidone deionized water solution is added, the mixture is stirred for 24 h in the dark, centrifuged at 3000 g for 15 min, and washed once with deionized water. The resulting precipitate is dispersed in 1 mL of deionized water to obtain a gold nanostar aqueous solution.
[0013] The gold seed aqueous solution can be prepared according to conventional methods. For example, the preparation method of the gold seed aqueous solution includes: preparing 100 mL of 1 mM HAuCl4 deionized aqueous solution, heating to boiling, adding 15 mL of 10 mg / mL sodium citrate deionized aqueous solution, and continuing to boil for 15 minutes to obtain the gold seed aqueous solution.
[0014] The present invention has found that by coating the surface of the gold nanostar with dense silica to make GNS@SiO2, silica can not only protect the integrity of the gold nanostar structure, but also effectively prevent the aggregation of the gold nanostar in the CTAB solution, which helps to form a uniform structure. If the gold nanostar directly reacts with CTAB, BTSE, and TEOS under alkaline conditions, a uniform and stable product cannot be obtained in the end due to the repulsion of the polymer (such as PVP, PEG) and CTAB introduced during the synthesis of the gold nanostar.
[0015] Specifically, the method of coating the surface of the gold nanostar with dense silica in step 2) comprises: reacting the gold nanostar with tetraethyl orthosilicate (TEOS) in the presence of deionized water, anhydrous ethanol and ammonia water to prepare GNS@SiO2.
[0016] Preferably, in step 2), in the step of coating the surface of the gold nanostar with dense silica, 1 mL of the gold nanostar aqueous solution is mixed with 3 mL of anhydrous ethanol, and then 72 μL of 28 wt% ammonia water is added. After magnetic stirring for 10 minutes, 20 μL of tetraethyl orthosilicate (dispersed in 1 mL of anhydrous ethanol, that is, a mixture of 20 μL of tetraethyl orthosilicate and 1 mL of anhydrous ethanol) is added dropwise, stirring is continued for 15-16 hours, centrifuged at 10,000 rpm for 10 minutes, washed twice with anhydrous ethanol and once with deionized water, and the resulting precipitate is dispersed in 7.5 mL of deionized water to obtain a GNS@SiO2 aqueous solution.
[0017] Specifically, step 3) the method for preparing GNS@SiO2@mSiO2 includes: in the presence of deionized water, anhydrous ethanol and aqueous ammonia, GNS@SiO2 reacts with tetraethyl orthosilicate (TEOS), dimethyldimethoxysilane (BTSE) and hexadecyltrimethylammonium bromide (CTAB) to prepare GNS@SiO2@mSiO2.
[0018] Preferably, step 3) the method for preparing GNS@SiO2@mSiO2 comprises: mixing 7.5 mL of GNS@SiO2 aqueous solution with 3 mL of anhydrous ethanol, adding 25 mg of hexadecyltrimethylammonium bromide, adding 100 μL of 28 wt% ammonia water after ultrasonic dissolution, stirring for 1 hour in a 35°C water bath, adding a mixture of 20 μL of tetraethyl orthosilicate and 20 μL of dimethyldimethoxysilane, continuing stirring for 4-5 hours, centrifuging at 10000 rpm for 10 minutes, washing twice with anhydrous ethanol, washing once with deionized water, and retaining the precipitate, which is GNS@SiO2@mSiO2, for later use.
[0019] Specifically, in step 4), GNS@SiO2@mSiO2 is contacted with a sodium carbonate solution having a concentration of 200-300 mg / mL (preferably 254.4 mg / mL) to prepare yolk-shell mesoporous silica-coated gold nanostars (GNS@YSMS).
[0020] Specifically, step 4) add 2.5 mL of Na2CO3 solution with a concentration of 254.4 mg / mL to GNS@SiO2@mSiO2, shake on a shaker at room temperature for 2 h, centrifuge at 10000 rpm for 10 min, wash twice with deionized water, retain the precipitate, add it to 7.9 mg / mL anhydrous methanol-sodium chloride solution (i.e., 7.9 mg sodium chloride per milliliter of anhydrous methanol), stir magnetically for 12 h, repeat 3 times to remove hexadecyltrimethylammonium bromide; finally, wash twice with anhydrous ethanol and freeze-dry the precipitate to obtain egg yolk shell mesoporous silica-coated gold nanostars for later use.
[0021] Preferably, the method for preparing the egg yolk shell mesoporous silica coated gold nanostars further comprises: 5) The yolk shell mesoporous silica-coated gold nanostars (GNS@YSMS) were amino-modified with 3-aminopropyltrimethoxysilane (APTES).
[0022] Experiments have shown that amino-modified egg yolk shell mesoporous silica-coated gold nanostars can significantly improve the loading capacity for metal ions, protein drugs and nucleic acid drugs.
[0023] Specifically, the method of step 5) comprises: reacting the egg yolk shell mesoporous silica-coated gold nanostars with 3-aminopropyltrimethoxysilane in the presence of anhydrous ethanol and ammonia water to prepare amino-modified egg yolk shell mesoporous silica-coated gold nanostars (amino-modified GNS@YSMS).
[0024] Preferably, in step 5), 40 mL of anhydrous ethanol is added to 20 mg of egg yolk shell mesoporous silica-coated gold nanostars, and after sufficient dissolution, 0.2 mL of 28 wt% ammonia water is added, stirred evenly, and then 0.15 mL of APTES is added, magnetic stirring is performed for 12 h, centrifuged at 10000 rpm for 10 min, washed twice with anhydrous ethanol, washed once with deionized water, and the precipitate is retained to obtain the aminated egg yolk shell mesoporous silica-coated gold nanostars (aminated GNS@YSMS).
[0025] In the present invention, the concentration of aqueous ammonia can be 25-28wt%.
[0026] The present invention also provides yolk shell mesoporous silica-coated gold nanostars prepared by the above method.
[0027] The present invention prepares GNS@YSMS in a mild way for the first time. Compared with naked GNS, the coating of YSMS improves its stability (including freeze-drying and photothermal stability) without significantly affecting the photothermal performance of GNS, thereby improving the accessibility of this drug-carrying platform. More importantly, the GNS@YSMS of the present invention can be loaded with a variety of drugs including metal ions, proteins and nucleic acids, demonstrating its potential as a multi-drug delivery platform.
[0028] The present invention also provides the use of the above-mentioned yolk shell mesoporous silica coated gold nanostar as a drug delivery platform. The above-mentioned yolk shell mesoporous silica coated gold nanostar (GNS@YSMS) can be used as a multi-drug delivery platform to effectively load chemotherapeutic drugs, photosensitizers, metal ions, proteins and nucleic acid drugs.
[0029] The present invention also provides a composition, comprising the egg yolk shell mesoporous silica coated gold nanostars and a supported object.
[0030] Specifically, the carried substance includes one or more of chemotherapeutic drugs, photosensitizers, metal ions, protein drugs, nucleic acid drugs, etc.
[0031] Specifically, the metal ions include iron ions (Fe 2+ ).
[0032] Specifically, the protein drug includes one or more of glucose oxidase (GOX) and horseradish peroxidase (HRP).
[0033] In some embodiments, the carrier is iron ions (Fe 2+ ) and the protein drug glucose oxidase (GOX).
[0034] The present invention selects Fe 2+ and GOX as model drugs and loaded into GNS@YSMS. 2+ GOX-mediated chemodynamic therapy and GNS-mediated photothermal therapy under laser irradiation synergistically inhibited the growth of cervical SiHa cells, while no obvious toxicity was observed using GNS@YSMS alone. The GNS@YSMS-based multidrug delivery platform was demonstrated to be highly efficient and safe.
[0035] The present invention converts the metal ion iron ion (Fe 2+ ) and protein drug glucose oxidase (GOX) were simultaneously introduced into the drug loading platform (GNS@YSMS) to prepare Fe 2+ and GOX's GNS@YSMS (GNS@YSMS-Fe 2+&GOX). The glucose content in the tumor microenvironment is higher than that in normal tissues. GOX catalyzes the glucose in the tumor to produce hydrogen peroxide in situ, and then Fe 2+ Catalyze H2O2 into highly toxic hydroxyl radicals (•OH), effectively inducing tumor cell death. GNS@YSMS-Fe 2+ &GOX combines Fe 2+ The H2O2-mediated chemodynamic therapy and GNS-mediated photothermal therapy showed significant synergistic killing effects on cervical cancer tumor cells SiHa in vitro and in vivo, with good safety. The experiment proved the potential of GNS@YSMS as a multi-drug carrier platform, and also provided a novel and effective option for the local treatment of cervical cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 Schematic diagram of the synthesis scheme of GNS@YSMS in a preferred embodiment of the present invention.
[0037] Figure 2 TEM images of GNS (a), GNS@SiO2 (b), GNS@MS (c), and GNS@YSMS (d) in preferred embodiments of the present invention.
[0038] Figure 3 The UV-visible spectra and photos of GNS (before and after freeze-drying) and GNS@YSMS (before and after freeze-drying) in the preferred embodiments of the present invention are shown.
[0039] Figure 4 Temperature curves of GNS and GNS@YSMS under 6 cycles of laser irradiation (40 min per cycle).
[0040] Figure 5 The temperature rise curves of GNS@YSMS with different concentrations under 808nm laser irradiation.
[0041] Figure 6 This is an electron microscope image of the silicon dioxide-coated gold nanostars prepared in Comparative Example 1 of the present invention.
[0042] Figure 7 This is an electron microscope image of the silicon dioxide-coated gold nanostars prepared in Comparative Example 2 of the present invention.
[0043] Figure 8 This is an electron microscope image of the silicon dioxide-coated gold nanostars prepared in Comparative Example 3 of the present invention.
[0044] Fig. 9 The nitrogen adsorption and desorption curves (a) and pore size distribution (b) of GNS@YSMS in a preferred embodiment of the present invention.
[0045] Fig.10Schematic diagram of GNS@YSMS as a platform for delivering metal ions, proteins and nucleic acids in a preferred embodiment of the present invention.
[0046] Fig.11 The loading efficiency (a) and zeta potential (b) of GNS@YSMS for glucose oxidase, horseradish peroxidase and iron ions in a preferred embodiment of the present invention.
[0047] Fig.12 The quantitative (a) and qualitative results (b) of DCFH-DA staining of SiHa tumor cells after GNS@YSMS acted on SiHa tumor cells in a preferred embodiment of the present invention.
[0048] Fig.13 The quantitative (a) and qualitative (b) detection results of the cell activity of SiHa tumor cells after different concentrations of GNS@YSMS acted on SiHa tumor cells in a preferred embodiment of the present invention.
[0049] Fig.14 Schematic diagram of the in vivo tumor inhibition experimental scheme.
[0050] Fig.15 GNS@YSMS-Fe in the preferred embodiment of the present invention 2+ &GOX in vivo temperature rise curve (a) and thermal imaging photo (b) under 808nm laser irradiation.
[0051] Fig.16 GNS@YSMS-Fe in the preferred embodiment of the present invention 2+ &GOX's inhibitory effect on mouse tumors, a, b, c, d, e and f are the mouse tumor photos at different time points, tumor volume, in vitro tumor photos at the endpoint, tumor mass and HE staining of tumor tissue, respectively.
[0052] Fig.17 The effect of GNS@YSMS on the activity of two cell lines (SiHa and Tu212) in a preferred embodiment of the present invention.
[0053] Fig.18 GNS@YSMS-Fe in the preferred embodiment of the present invention 2+ &The effects of GOX injection on blood physiological and biochemical indices in mice. DETAILED DESCRIPTION
[0054] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.
[0055] Preparation of gold seed aqueous solution: Prepare 100 mL of 1 mM HAuCl4 deionized aqueous solution, place in a round-bottom flask, heat to boiling with an electric heating mantle, add 15 mL of 10 mg / mL sodium citrate deionized aqueous solution, continue boiling for 15 minutes, keep the system stable, and obtain the gold seed aqueous solution. Store at 4°C for future use.
[0056] Example 1
[0057] 1) Preparation of gold nanostars (GNS)
[0058] Prepare 100 mL of 0.25 mM HAuCl4 deionized water solution, add 8.33 μL of 37% concentrated hydrochloric acid, mix by magnetic stirring, then add 1 mL of gold seed aqueous solution, continue stirring, and add 1 mL of 3 mM AgNO3 deionized water solution and 0.5 mL of 100 mM ascorbic acid deionized water solution at the same time. The solution changes from red to dark blue. After reacting for about 1 min, add 0.3 mL of 15 mg / mL PVP deionized water solution, stir for 24 h in the dark, centrifuge at 3000 g for 15 min, wash once with deionized water, and disperse the resulting precipitate in 1 mL of deionized water to obtain a gold nanostar aqueous solution.
[0059] 2) Preparation of GNS@SiO2
[0060] After mixing 1 mL of gold nanostar aqueous solution with 3 mL of anhydrous ethanol, add 72 μL of ammonia water (28 wt%), and add 20 μL of TEOS (dispersed in 1 mL of anhydrous ethanol) dropwise after magnetic stirring for 10 min. Continue stirring for 15-16 h, centrifuge at 10,000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and disperse the precipitate in 7.5 mL of deionized water to obtain the GNS@SiO2 aqueous solution for later use.
[0061] 3) Preparation of GNS@SiO2@mSiO2
[0062] Mix 7.5 mL of the GNS@SiO2 aqueous solution in step 2) with 3 mL of anhydrous ethanol, add 25 mg of CTAB, dissolve under ultrasound, add 100 μL of ammonia water (28 wt%), stir for 1 h in a water bath at 35 °C, add a mixture of 20 μL of TEOS and 20 μL of BTSE, continue stirring for 4-5 h, centrifuge at 10000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and retain the precipitate, which is GNS@SiO2@mSiO2, for later use.
[0063] 4) Preparation of GNS@YSMS (Na2CO3 etching method)
[0064] Take step 3) GNS@SiO2@mSiO2, add 2.5mL of 254.4mg / mL Na2CO3 solution, shake on a shaker at room temperature for 2h, centrifuge at 10000rpm for 10min, wash twice with deionized water, keep the precipitate, add it to anhydrous methanol-sodium chloride solution (7.9mg / mL) and stir it magnetically for 12h, repeat 3 times to remove CTAB; wash twice with anhydrous ethanol and freeze-dry the precipitate to obtain egg yolk shell mesoporous silica-coated gold nanostars (GNS@YSMS) for later use.
[0065] 5) APTES amination
[0066] Weigh 20 mg of the freeze-dried material in step 4), add 40 mL of anhydrous ethanol, add 0.2 mL of ammonia water after it is fully dissolved, stir evenly, add 0.15 mL of APTES, stir magnetically for 12 h, centrifuge at 10000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and retain the precipitate, which is the amino-modified egg yolk shell mesoporous silica-coated gold nanostars (amino-modified GNS@YSMS).
[0067] Figure 2 d is a transmission electron microscopy image of the yolk-shell mesoporous silica-coated gold nanostar (GNS@YSMS) prepared in this example. TEM shows a spherical structure with GNS yolk and MS shell.
[0068] Figure 2 b is a transmission electron microscope image of GNS@SiO2 prepared in step 1) of this example 1. A 5 nm dense silica layer is pre-coated on GNS. At this time, GNS@SiO2 can be well coated by MS (mesoporous silica), and GNS@MS shows a clear spherical structure under TEM with an average diameter of 200 nm ( Figure 2 c).
[0069] Figure 2 a is a transmission electron microscopy image of the gold nanostar (GNS) prepared in step 1), which shows a clear star-shaped structure.
[0070] The preparation process of GNS@YSMS is shown in Figure 1 .
[0071] Comparative Example 1 Gold Nanostars without PVP Functionalization
[0072] The difference from Example 1 is only in step 1). The method for preparing gold nanostars in this comparative example is as follows: Prepare 100 mL of 0.25 mM HAuCl4 deionized water solution, add 8 μL of 37% concentrated hydrochloric acid, mix well, then add 5 mL of the above gold seed, stir gently (700 rpm), then add 1 mL of 3 mM AgNO3 and 0.5 mL of 100 mM ascorbic acid, the solution changes from red to blue-green, then add 100 μL of 5000 mM PEG-SH (thiolated polyethylene glycol), stir for 15 min, centrifuge at 4000 rpm for 25 min, take the precipitate, disperse in 3 mL of deionized water, and store at 4°C for later use.
[0073] Using the gold nanostars prepared in this comparative example, the same method as step 2) of Example 1 was used to prepare the gold nanostars coated with silicon dioxide.
[0074] Electron micrographs see Figure 6 , and found that most of the silica was not coated on the surface of the gold nanostars.
[0075] Comparative Example 2 No SiO2 coating (i.e. one-step method)
[0076] The only difference from Example 1 is that step 2 is omitted), which is as follows: Mix 7.5 mL of gold nanostar aqueous solution with 3 mL of anhydrous ethanol, add 25 mg of CTAB, dissolve under ultrasound, add 100 μL of ammonia water (28 wt%), stir for 1 h in a 35 °C water bath, add a mixture of 20 μL of TEOS and 20 μL of BTSE, continue stirring for 4-5 h, centrifuge at 10000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and keep the precipitate for later use.
[0077] Take the precipitate, add 2.5 mL of 254.4 mg / mL Na2CO3 solution, shake on a shaker at room temperature for 2 h, centrifuge at 10000 rpm for 10 min, wash twice with deionized water, keep the precipitate, add anhydrous methanol-sodium chloride solution (7.9 mg / mL) and stir magnetically for 12 h, repeat 3 times to remove CTAB; wash twice with anhydrous ethanol, take out the precipitate and freeze-dry it for later use.
[0078] Weigh 20 mg of freeze-dried material, add 40 mL of anhydrous ethanol, add 0.2 mL of ammonia water after fully dissolving, stir evenly, add 0.15 mL of APTES, stir magnetically for 12 h, centrifuge at 10000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and retain the precipitate to obtain egg yolk shell mesoporous silica-coated gold nanostars.
[0079] Electron micrographs see Figure 7 The results showed that some yolk shell mesoporous silica centers were not coated with gold nanostars, some yolk shell mesoporous silica centers were coated with multiple gold nanostars, and the protrusions on the surface of the gold nanostars became shorter.
[0080] The synthesis of GNS@YSMS in this comparative example adopts a one-step method, that is, GNS directly reacts with CTAB, BTSE, and TEOS under alkaline conditions. Due to the repulsion between the polymers (such as PVP, PEG) introduced during the synthesis of GNS and CTAB, a homogeneous product cannot be obtained in the end.
[0081] Comparative Example 3: No Sodium Carbonate Etching
[0082] The only difference from Example 1 is step 4), which is as follows: Take the GNS@SiO2@mSiO2 in step 3 of Example 1, wash once with anhydrous ethanol, wash once with deionized water, disperse the collected precipitate in 10 mL of deionized water, incubate at 60°C in a water bath for 8 h, centrifuge at 10000 rpm for 10 min, wash 3 times with anhydrous ethanol, and keep the precipitate. Take 60 mL of anhydrous ethanol, add 120 μL of concentrated HCl (37%), and mix well. Add the collected precipitate to the mixture, stir at 60°C in a water bath for 3 h to remove CTAB, and obtain the yolk shell mesoporous silica-coated gold nanostars.
[0083] Electron micrographs see Figure 8 The results showed that the star-shaped structure of gold nanostars was destroyed and turned into a spherical structure, which lost the advantage of gold nanostars in high near-infrared absorption.
[0084] Experimental Example 1: Stability Study
[0085] Compared with GNS, GNS@YSMS exhibits excellent stability under various conditions
[0086] Stability is crucial for clinical applications. In this experiment, the freeze-thaw and photothermal stability of GNS and GNS@YSMS were evaluated.
[0087] Aqueous solutions of two nanoparticles, GNS and GNS@YSMS (prepared in Example 1), with the same gold mass were prepared. 2.5 mL of each solution was centrifuged, the precipitate was freeze-dried, and then redissolved in 2.5 mL of deionized water. 2 mL of each of the four solutions before and after freeze-drying were placed in quartz cuvettes, and the absorption spectra of the four samples at 200-1100 nm were measured using a UV-1800 ultraviolet-visible spectrophotometer.
[0088] Take 200μL of GNS and GNS@YSMS aqueous solutions respectively and add them into a small transparent glass tube made in the laboratory. The tube wall thickness is about 0.5mm and the height is about 2cm. The tube mouth is finally sealed with a sealing film to prevent the evaporation of water and the loss of heat during the experiment. Then put the sealed glass tube into a matching foam tank, and the initial temperature is controlled at about 25℃. Use an 808nm laser to irradiate vertically downward from about 10cm above the glass tube. The two solutions are heated and cooled by laser irradiation six times respectively. The infrared thermal imager is used to track and measure the liquid temperature in the tube.
[0089] 200 μL of deionized water and GNS@YSMS aqueous solution (0.05 and 0.1 mg / mL) were taken respectively and placed in glass tubes. After sealing, they were irradiated with 808 nm laser. The liquid temperature at each time point was recorded using an infrared thermal imager at 0, 0.5, 1, 2, 3, 5, 10, 15 and 20 min during the laser irradiation process. The test was repeated three times for each liquid and the average value was taken.
[0090] GNS@YSMS showed similar physical appearance and no obvious aggregation after freeze-drying, while GNS had obvious aggregation after freeze-drying, which was consistent with the UV-visible absorption spectrum ( Figure 3 In addition, the photothermal performance remained almost unchanged after six ON / OFF laser cycles, demonstrating the high photothermal stability of GNS@YSMS ( Figure 4 ). At the same time, GNS@YSMS with different concentrations showed rapid heating under 808nm laser irradiation ( Figure 5 ). These results all indicate that GNS@YSMS has stable performance and excellent photothermal performance.
[0091] Experimental Example 2 Investigation of drug loading capacity
[0092] GNS@YSMS has the ability to load multiple drugs.
[0093] Considering the yolk-shell mesoporous structure of positively charged GNS@YSMS, this study explored its potential as a platform for the delivery of various drugs.
[0094] Prepare 0.2 mol / mL FeSO4 aqueous solution, 8 mg / mL GNS@YSMS aqueous solution, 10 mg / mL GOX aqueous solution and HRP aqueous solution.
[0095] Fe 2+ : Take 0.5 mL of the above GNS@YSMS aqueous solution, 0.25 mL of FeSO4 aqueous solution, and then add 0.25 mL of deionized water, mix well, and place in a shaker at room temperature in the dark at 200 rpm for 2 h. After centrifugation and washing, GNS@YSMS-Fe 2+ .
[0096] GOX loading: Take 0.25 mL of the above GNS@YSMS aqueous solution, 0.04 mL of GOX aqueous solution, and then add 0.75 mL of deionized water. After mixing, place it in a shaker at room temperature away from light at 200 rpm for 1 h. After centrifugation and washing with water, GNS@YSMS-GOX was obtained.
[0097] Loading HRP: Take 0.25 mL of the above GNS@YSMS aqueous solution, 0.04 mL of HRP aqueous solution, and then add 0.75 mL of deionized water. After mixing, place it in a shaker at room temperature away from light at 200 rpm for 1 h. After centrifugation and washing with water, GNS@YSMS-HRP was obtained.
[0098] The N2 absorption-desorption isotherms and the corresponding pore size distribution further demonstrate the clear mesoporous structure ( Fig. 9 , a and b), the surface area, pore volume and average pore size of GNS@YSMS are 944.00 m 2 / g, 1.13cc / g and 3.94nm. Next, metal ions, proteins and nucleic acid drugs were loaded into GNS@YSMS ( Fig.10 ), the results showed that protein drugs represented by glucose oxidase and horseradish peroxidase and Fe 2+ The metal ion drugs represented by can be efficiently loaded into GNS@YSMS, with drug loading rates of 4.07%, 4.37% and 1.96%, respectively ( Fig.11 a). After loading protein drugs, the surface potential of GNS@YSMS decreases, and after loading metal ions, the surface potential of GNS@YSMS increases ( Fig.11 b). These results suggest that GNS@YSMS can serve as a universal drug delivery platform and play an important role in the multimodal treatment of tumors.
[0099] Experimental Example 3 GNS@YSMS-Fe 2+ GOX-mediated photothermal therapy and chemodynamic therapy synergistically inhibit tumor cell growth
[0100] To confirm the synergistic inhibitory effect of GNS@YSMS on tumor growth, GOX and Fe 2+ At the same time, it was loaded into GNS@YSMS to obtain GNS@YSMS-Fe 2+ &GOX.
[0101] GNS@YSMS-Fe 2+The preparation method of GOX is as follows: 0.5 mL of 8 mg / mL GNS@YSMS aqueous solution, 0.25 mL of 0.2 mol / mL FeSO4 aqueous solution, and 0.25 mL of deionized water are added. After mixing, the mixture is placed in a room temperature shaker protected from light at 200 rpm for 2 h. Then, 0.08 mL of 10 mg / mL GOX aqueous solution is added, and the mixture is shaken for 1 h. After centrifugation and washing, GNS@YSMS-Fe 2+ &GOX.
[0102] Preparation method of GNS@YSMS-GOX: Take 0.25 mL of 8 mg / mL GNS@YSMS aqueous solution, 0.04 mL of 10 mg / mL GOX aqueous solution, and then add 0.75 mL of deionized water, mix well, place in a room temperature shaker away from light, shake at 200 rpm for 1 hour, centrifuge and wash with water to obtain GNS@YSMS-GOX. GNS@YSMS-Fe 2+ Preparation method: Take 0.5 mL of 8 mg / mL GNS@YSMS aqueous solution, 0.25 mL of 0.2 mol / mL FeSO4 aqueous solution, and then add 0.25 mL of deionized water. After mixing, place in a shaker at room temperature away from light, shake at 200 rpm for 2 h, and centrifuge and wash with water to obtain GNS@YSMS-Fe 2+ .
[0103] In vitro cell experiments showed that only when GOX and Fe 2+ When samples are loaded at the same time, the level of intracellular reactive oxygen species (ROS) can be significantly increased ( Fig.12 , a and b), indicating that only when GOX catalyzes glucose into H2O2 and Fe 2+ When H2O2 is catalyzed to •OH, the level of reactive oxygen in the cell can increase. 2+ Neither of them could significantly increase the ROS level of cells, which preliminarily verified that GOX and Fe 2+ In addition, GNS-mediated photothermal therapy was introduced. At the cellular level, we observed a synergistic killing effect of the two treatment modes. Specifically, 150 μg / mL GNS@YSMS-Fe 2+ The viability of SiHa cells treated with GOX was 44.9%, and that of SiHa cells treated with GNS@YSMS+L was 60.1%. 2+ &The cell viability after GOX+L treatment was only 12.3% ( Fig.13 , a and b), indicating that the combination of the two treatment modes can significantly kill SiHa cells in vitro.
[0104] Experimental Example 4 GNS@YSMS-Fe 2+GOX-mediated photothermal therapy and chemodynamic therapy inhibit solid tumor growth
[0105] In order to further investigate the GNS@YSMS-Fe 2+ The therapeutic effect of GOX on solid tumors. In this experiment, a SiHa cell transplant tumor model was constructed. When the tumor volume grew to 50 mm 3 Different therapeutic agents were injected into the tumor at different times, and laser irradiation was performed 6h and 48h after injection ( Fig.14 ).
[0106] After cervical cancer cells were cultured to the logarithmic phase, the cells were digested and collected into a 1.5 mL centrifuge tube at a concentration of about 10 7 / mL. Use a syringe to draw 50μL of cell suspension and inject it subcutaneously into the right forelimb of nude mice. When the tumor grows to about 50mm 3 You can start the experiment in about 2 seconds.
[0107] Twenty nude mice bearing cervical cancer tumors were randomly divided into four groups and injected with 50 μL PBS solution, 50 μL GNS@YSMS-Fe 2+ &GOX (1mg / mL), 50μL GNS@YSMS (1mg / mL), 50μL GNS@YSMS-Fe 2+ &GOX (1 mg / mL), namely “Tumor + PBS” group, “Tumor +GNS@YSMS-Fe 2+ &GOX” group, “GNS@YSMS + L” group and “GNS@YSMS-Fe 2+ &GOX + L” group. The first laser irradiation (10 min) was performed 6 h after tumor injection, and the temperature of the tumor site was recorded using an infrared thermal imager (0, 0.5, 1, 2, 3, 4, 5 and 10 min). The second laser irradiation (10 min) was performed 48 h after tumor injection. Starting from the day of injection, the size of the mouse tumor was measured every 2 days and photographed. The mice were killed on the 16th day, and the tumors were removed after dissection for photographing and weighing. Finally, the tumor tissue was fixed for subsequent histological analysis.
[0108] During the first laser irradiation treatment, the temperature of the mouse solid tumor site was monitored. The results showed that the temperature of the mouse tumor treated with GNS@YSMS quickly reached about 49°C after laser irradiation, while the simple PBS and laser irradiation treatment could not significantly increase the temperature of the mouse tumor, and could only increase the temperature to about 40°C ( Fig.15 , a and b). When the local temperature of the tumor reaches 43°C, the growth of tumor cells can be inhibited. Therefore, GNS@YSMS combined with laser irradiation can effectively inhibit tumor growth. Subsequent mouse tumor photos ( Fig.16 a) and mouse tumor growth curve ( Fig.16 , b and c) confirmed that GNS@YSMS combined with laser irradiation significantly inhibited the growth of solid tumors in mice, and the tumor growth inhibition rate (TGI) was 66.1% after 16 days of treatment. 2+ The TGI after GOX treatment is 53.2%, GNS@YSMS-Fe 2+ &GOX combined with laser irradiation, i.e. GNS photothermal therapy combined with GOX and Fe 2+ After mediated chemodynamic treatment, the TGI was 92.1%, proving that the combination of the two treatment modes significantly inhibited the growth of SiHa solid tumors. The photos and weights of isolated mouse tumors also confirmed the above results ( Fig.16 , d and e). It was observed from the results of HE staining of mouse tumor tissue ( Fig.16 f) The tumor tissue in the PBS group was dense, the tumor cell nucleus and cytoplasm were intact, and the structure was clear, indicating that the tumor was growing vigorously at this time; GNS@YSMS-Fe 2+ &GOX, GNS@YSMS + L and GNS@YSMS-Fe 2+ The loss of cytoplasm and nucleus in the GOX + L group and the enlarged gap between cells indicate that the tumor cells are in a state of apoptosis and necrosis. 2 + The necrosis of GNS@YSMS-Fe 2+ &GOX can effectively inhibit the growth of SiHa solid tumors under laser excitation.
[0109] Experimental Example 5 Both GNS@YSMS and GNS@YSMS-Fe2+&GOX showed good biosafety
[0110] In confirming that GNS@YSMS-Fe 2+ &Based on the therapeutic effect of GOX, safety is the key issue that needs to be examined. Only by ensuring a certain level of safety can the treatment appear more valuable and meaningful.
[0111] SiHa and Tu212 cells were cultured to the logarithmic phase, digested with trypsin, and then subcultured into the sample wells of a 96-well cell culture plate. The concentration of the cell suspension was adjusted to about 6,000 cells per well, with a total of 2 plates, each with 25 wells. The culture plates were placed in a 37°C constant temperature incubator containing 5% CO2 overnight to allow the cells to adhere to the wall. The culture medium in the wells of the culture plate was removed, and 200 μL of serum-free culture medium solutions with concentrations of 0.1, 0.2, 0.3, and 0.4 mg / mL of GNS@YSMS were added, respectively, and a serum-free culture medium solution without nanomaterials was used as a control. Five wells in each group were used as replicates. After that, the 96-well plate was placed in a cell culture incubator and cultured for 24 h at 5% CO2 and 37°C, and then the cell activity of each group was detected.
[0112] Nine healthy female mice were randomly divided into three groups. One group was the untreated group, and blood was directly taken to detect various physiological and biochemical indicators in the blood as a control; the other two groups were subcutaneously injected with GNS@YSMS-Fe 2+ &GOX (1 mg / mL, 50 μL), blood was collected on the 1st and 7th days after injection to detect various physiological and biochemical blood indicators.
[0113] Based on this, this experiment first analyzed the effects of different concentrations of GNS@YSMS on the activity of two cell lines, SiHa and Tu212 cell lines, in vitro ( Fig.17 ), the results showed that even 400 μg / mL of GNS@YSMS had no significant effect on the growth of both cell lines, confirming that the GNS@YSMS drug delivery platform has good biocompatibility. We further analyzed the subcutaneous injection of GNS@YSMS-Fe 2+ Blood physiological and biochemical indicators after 1 day and 7 days of GOX ( Fig.18 ), compared with healthy mice, there was no significant difference in various indicators, proving that GNS@YSMS-Fe 2+ &GOX treatment had little effect on the overall physiological state of mice and had good biocompatibility.
[0114] In summary, the present invention constructs a drug-carrying platform with excellent photothermal performance, which can be combined with a variety of treatment modes. After combining with chemodynamic therapy, the results of in vivo and in vitro treatment experiments have confirmed its efficient tumor inhibition effect, and at the same time, it has good biocompatibility. This treatment system has potential clinical application value for the combined treatment of cervical cancer.
[0115] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A yolk shell mesoporous silica coated gold nanostar, characterized in that: include: Core, gold nanostar; The shell is mesoporous silica.
2. The yolk shell mesoporous silica coated gold nanostar according to claim 1, characterized in that: The gold nanostar is coated in the mesoporous silica, the diameter of the core is 50-100 nm, and the thickness of the shell is 75-150 nm.
3. The method for preparing the yolk shell mesoporous silica coated gold nanostars according to claim 1 or 2, characterized in that: include: 1) Preparation of gold nanostars; 2) coating the surface of the gold nanostar with dense silica to prepare GNS@SiO2; 3) GNS@SiO2 reacts with ethyl orthosilicate, dimethyldimethoxysilane and hexadecyltrimethylammonium bromide to prepare GNS@SiO2@mSiO2; 4) GNS@SiO2@mSiO2 was etched with sodium carbonate to produce yolk-shell mesoporous silica-coated gold nanostars.
4. The method according to claim 3, characterized in that include: (1) In a solution, HAuCl4, concentrated hydrochloric acid and gold seeds are first reacted; then AgNO3 and ascorbic acid are added to react; finally, polyvinyl pyrrolidone is added to react to obtain gold nanostars; (2) reacting the gold nanostars with tetraethyl orthosilicate in the presence of deionized water, anhydrous ethanol and ammonia water to prepare GNS@SiO2; (3) In the presence of deionized water, anhydrous ethanol and ammonia water, GNS@SiO2 reacts with ethyl orthosilicate, dimethyldimethoxysilane and hexadecyltrimethylammonium bromide to prepare GNS@SiO2@mSiO2; (4) The GNS@SiO2@mSiO2 was contacted with a sodium carbonate solution with a concentration of 200-300 mg / mL to prepare yolk-shell mesoporous silica-coated gold nanostars.
5. The method according to claim 4, characterized in that include: S1. Prepare 100 mL of 0.25 mM HAuCl4 deionized water solution, add 8.33 μL of 36%-38% concentrated hydrochloric acid, mix by magnetic stirring, then add 1 mL of gold seed aqueous solution, continue stirring, and add 1 mL of 3 mM AgNO3 deionized water solution and 0.5 mL of 100 mM ascorbic acid deionized water solution at the same time. After reacting for 1 min, add 0.3 mL of 15 mg / mL polyvinyl pyrrolidone deionized water solution, stir for 24 h in dark, centrifuge at 3000 g for 15 min, wash once with deionized water, and disperse the obtained precipitate in 1 mL of deionized water to obtain a gold nanostar aqueous solution; The preparation method of the gold seed aqueous solution comprises: preparing 100 mL of a 1 mM HAuCl4 deionized aqueous solution, heating to boiling, adding 15 mL of a 10 mg / mL sodium citrate deionized aqueous solution, and continuing to boil for 15 minutes to obtain a gold seed aqueous solution; S2, after mixing 1 mL of gold nanostar aqueous solution with 3 mL of anhydrous ethanol, add 72 μL of 28 wt% ammonia water, magnetically stir for 10 min, add 20 μL of tetraethyl orthosilicate dropwise, continue stirring for 15-16 h, centrifuge at 10000 rpm for 10 min, wash twice with anhydrous ethanol, wash once with deionized water, and disperse the obtained precipitate in 7.5 mL of deionized water to obtain a GNS@SiO2 aqueous solution; S3, 7.5mL of GNS@SiO2 aqueous solution was mixed with 3mL of anhydrous ethanol, 25mg of hexadecyltrimethylammonium bromide was added, 100μL of 28wt% ammonia water was added after ultrasonic dissolution, and the mixture was stirred for 1h in a water bath at 35℃, and 20μL of a mixture of ethyl orthosilicate and dimethyldimethoxysilane was added, and the mixture was stirred for 4-5h, and centrifuged at 10000rpm for 10min, and washed twice with anhydrous ethanol and once with deionized water, and the precipitate was retained, which was GNS@SiO2@mSiO2; S4. Add 2.5 mL of Na2CO3 solution with a concentration of 254.4 mg / mL to GNS@SiO2@mSiO2, shake on a shaker at room temperature for 2 h, centrifuge at 10000 rpm for 10 min, wash twice with deionized water, keep the precipitate, add it to 7.9 mg / mL anhydrous methanol-sodium chloride solution, stir magnetically for 12 h, repeat 3 times to remove hexadecyltrimethylammonium bromide; finally, wash twice with anhydrous ethanol and freeze-dry the precipitate to obtain egg yolk shell mesoporous silica-coated gold nanostars; Among them, 7.9 mg / mL anhydrous methanol-sodium chloride solution means: 7.9 mg sodium chloride is contained in each milliliter of anhydrous methanol.
6. The method according to claim 3, characterized in that Also includes: 5) The yolk shell mesoporous silica coated gold nanostars were aminated with 3-aminopropyltrimethoxysilane; Specifically, in the presence of anhydrous ethanol and ammonia water, the egg yolk shell mesoporous silica-coated gold nanostars are reacted with 3-aminopropyltrimethoxysilane to prepare the amino-modified egg yolk shell mesoporous silica-coated gold nanostars.
7. A yolk shell mesoporous silica coated gold nanostar, characterized in that: Prepared by the method according to any one of claims 3 to 6.
8. Use of the yolk shell mesoporous silica coated gold nanostars as a drug delivery platform according to any one of claims 1-2 and 7; Optionally, the cargo includes one or more of chemotherapeutic drugs, photosensitizers, metal ions, proteins, and nucleic acid drugs.
9. A composition, characterized in that It comprises the yolk shell mesoporous silica coated gold nanostars and a supported object as described in any one of claims 1 to 2 and 7; Optionally, the cargo includes one or more of chemotherapeutic drugs, photosensitizers, metal ions, proteins, and nucleic acid drugs.
10. The composition according to claim 9, characterized in that The object to be carried is selected from iron ions and protein drug glucose oxidase.
Citation Information
Patent Citations
Preparation method of composite material of yolk-eggshell structure
CN107096545A
Method for preparing mesoporous silica coated gold nanoparticle drug carrier
CN107737336A
Gold-nanostar core / hollow silicon shell drug-loading nano-platform and preparation method and application thereof
CN109675033A
Preparation method of silica-coated gold nanoparticles with yolk shell structure
CN117505849A
Spherical nanoparticles consisting of yolk-shell type single gold nanodot core and silica shell and synthesis method thereof
KR101465440B1
Cited By
Physiological pressure driven piezoelectric catalysis treatment nano-drug delivery system with pH response drug release function as well as preparation method and application of physiological pressure driven piezoelectric catalysis treatment nano-drug delivery system
CN122516145A
